Compare NRG Energy Inc (NRG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Regeneron Pharmaceuticals Inc — how do they compare? NRG Energy Inc trades at $120.38 (market cap $24.83B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.4× NRG Energy Inc's market cap, and NRG Energy Inc pays the higher dividend (1.61%). Which is the better fit depends on your goals.
| NRG | REGN | |
|---|---|---|
Market Cap | $24.83B | $83.19B |
Sector | Utilities | Health |
52-Week High | $184.03 | $812.27 |
52-Week Low | $117.04 | $555.51 |
Enterprise Value | $48.79B | $77.90B |
Dividend Yield | 1.61% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $118.13, down 0.77% on the day, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. The company reported Q2 2026 adjusted EBITDA of $1.2 billion, up 34% year-over-year, and is advancing a 1.2-GW Texas data-center power project to drive growth. Valuation metrics show a P/E of 30.76 and P/S of 0.72, with a net income margin of 2.56% for 2025.
The outlook is mixed: strong analyst consensus (69% buy ratings) and a $207.83 price target suggest upside, but technical weakness, rising debt, and execution risks on new projects pose challenges. Revenue growth to $33.1B in 2026 and strategic investments in data center demand support long-term potential, though interest costs and leverage require monitoring.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
